Our Leadership Team
Our executive team represents a unique combination of expertise in biotechnology and pharmaceuticals, healthcare finance management and patent strategy. Together, we have more than 65 years of experience in science, research, business and biotechnology at a range of respected companies including Avalon, GeneLogic, Boehringer Mannheim. We founded AccelBio to revolutionize the process of cell manufacturing for research and clinical therapeutic development.
Jason Dictenberg, PhD, CEO
Jason Dictenberg is an entrepreneur and scientist with over 15 years of experience in the life sciences sector, with strong business and leadership skills in biopharmaceutical strategy and operational planning. He holds a BA in molecular cell biology and mathematics from Brandeis University, where his research into lipid biochemistry led to the discovery of the hyper-cholesterolemic effects of trans-fatty acids, and the formulation of EarthBalance Blends for improved human cardiology and cholesterol homeostasis. Dr. Dictenberg holds a PhD in Molecular Medicine from the University of Massachusetts Medical Center, where his oncology discovery work led to groundbreaking function and new target strategy for the animal cell division organelle, the centrosome. During a fellowship at Albert Einstein College of Medicine (AECOM), he directed research on the human genetics of learning and memory and raised both private and public funds to investigate pharmacologic regulation of gene expression in neurologic disease, including autism, Alzheimer's disease, epilepsy and psychiatric mood disorders. He has raised millions of dollars to investigate cancer biology and developmental brain disorders, including Federal grants from the National Institutes of Health and National Science Foundation. Prior to AccelBio, he previously held faculty positions and served as a consultant and director to several biopharmaceutical companies, healthcare fund management firms and academic centers including City University, Weill Cornell Medical School, Amylin Pharmaceuticals, The Scripps Research Institute, Albert Einstein College of Medicine, and Array Capital. Dr. Dictenberg is an author of over 100 primary research papers, abstracts and conference presentations, and is the recipient of the Albert Einstein Scholar Award from AECOM, as well as the Young Investigator Award from the International Society for Developmental Neuroscience.
Board of Directors
John J. Doll
Former Commissioner, United States Patent and Trademark Office (USPTO)
John Doll was former Commissioner of the United States Patent and Trademark Office (USPTO). Previously, he has served as the Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO. As Commissioner, he was appointed by the US Secretary of Commerce and served as the Chief Operating Officer for all aspects of the patent related operations, planning and policy with the mission of the properly applying the patent laws and regulations of the United States in the examination of patent applications. He oversaw a budget of $1.3 billion and a staff of over 7000 employees. He was also responsible for Patent's strategic planning and execution, labor management relations, customer outreach, congressional relations, public advisory committee relations, and patent policy formulation.
Michael Brennan, MD, PhD
Managing Director, Pearl Street Venture Funds
Michael Brennan is the Managing Director of Pearl Street Venture Funds. He was previously a General Partner at Oxford Bioscience Partners. Prior to that, he was the President and Chief Executive Officer of Gene Logic (NASDAQ: GLGC). During Dr. Brennan's time at Gene Logic, he built the company from a start-up to a public company that achieved a market capitalization of over $5 billion. He raised three rounds of venture capital and led Gene Logic to an IPO in November, 1997 and a large secondary public offering in January 2000. Dr. Brennan's previous experience includes six years in the biopharmaceutical industry, where he has served as Vice President, Business Development for Boehringer Mannheim Therapeutics. Dr. Brennan received a B.S. in biochemistry, a PhD in neurobiology and MD from the University of Witwatersrand, Johannesburg, South Africa.